Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 8/20 | 0.50 |
| ▸ | PTGS2 | P35354 | 8/20 | 0.50 |
| ▸ | BCHE | P06276 | 6/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | LTA4H | P09960 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | NOS3 | P29474 | 1/20 | 0.34 |
| ▸ | NOS1 | P29475 | 1/20 | 0.34 |
| ▸ | PPARG | P37231 | 1/20 | 0.34 |
| ▸ | PPARA | Q07869 | 1/20 | 0.34 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.34 |
| ▸ | ESR1 | P03372 | 1/20 | 0.33 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.33 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.33 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.33 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.33 |
| ▸ | TOP2A | P11388 | 1/20 | 0.33 |
| ▸ | TOP2B | Q02880 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6394314 | 0.84 | PTGS2 (0.57) | ACHEPTGS2BCHENPC1RAB9A | |
| SCHEMBL5796026 | 0.84 | PTGS2 (0.47) | ACHEPTGS2BCHENPC1RAB9A | |
| SCHEMBL13237042 | 0.83 | ACHE (0.49) | ACHEPTGS2BCHENPC1RAB9A | |
| SCHEMBL14706788 | 0.82 | PPARA (0.37) | ACHEPTGS2BCHELTA4HTSHR | |
| SCHEMBL2235768 | 0.81 | ACHE (0.45) | ACHEPTGS2BCHELTA4HPPARA | |
| SCHEMBL12694341 | 0.81 | LTA4H (0.36) | ACHEPTGS2BCHENPC1RAB9A | |
| SCHEMBL16407983 | 0.80 | CYP4A11 (0.46) | ACHEPTGS2BCHEPPARAESR1 | |
| SCHEMBL6948598 | 0.80 | ACHE (0.44) | ACHEPTGS2BCHENPC1RAB9A | |
| SCHEMBL3126542 | 0.79 | ACHE (0.46) | ACHEPTGS2BCHENPC1RAB9A | |
| SCHEMBL6947245 | 0.79 | ACHE (0.46) | ACHEPTGS2BCHENPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220119350-A1 | COMPOUNDS FOR THE TREATMENT OF OCULAR DISEASE | GLAUKOS CORPORATION | 2022-04-21 | — | — | US | disclosed |
| US-11092604-B2 | Glucose sensor molecule | BAXTER INTERNATIONAL INC. (US) | 2021-08-17 | — | — | US | disclosed |
| US-11092604-B2 | Glucose sensor molecule | BAXTER INTERNATIONAL INC. (US) | 2021-08-17 | — | — | US | disclosed |
| US-10927104-B2 | Ether compounds and uses thereof | BIOTHERYX, INC. (US) | 2021-02-23 | — | — | US | disclosed |
| US-20200231582-A1 | ETHER COMPOUNDS AND USES THEREOF | BIOTHERYX, INC. | 2020-07-23 | — | — | US | disclosed |
| EP-3672955-A1 | ETHER COMPOUNDS AND USES THEREOF | Biotheryx Inc. (US) | 2020-07-01 | — | — | EP | disclosed |
| CN-111247138-A | Ether compound and use thereof | 拜欧赛里克斯公司 | 2020-06-05 | — | — | CN | disclosed |
| WO-2019040274-A1 | ETHER COMPOUNDS AND USES THEREOF | BIOTHERYX, INC. (US) | 2019-02-28 | — | — | WO | disclosed |
| EP-2663570-B1 | GLUCOSE SENSOR MOLECULE | LIGHTSHIP MEDICAL LTD (GB) | 2018-07-18 | — | — | EP | disclosed |
| EP-2663570-B1 | GLUCOSE SENSOR MOLECULE | LIGHTSHIP MEDICAL LTD (GB) | 2018-07-18 | — | — | EP | disclosed |
| WO-2012095628-A1 | GLUCOSE SENSOR MOLECULE | LIGHTSHIP MEDICAL LIMITED (GB) | 2012-07-19 | — | — | WO | disclosed |
| WO-2012095628-A1 | GLUCOSE SENSOR MOLECULE | LIGHTSHIP MEDICAL LIMITED (GB) | 2012-07-19 | — | — | WO | disclosed |
| WO-2008096129-A1 | NITROGEN CONTAINING HETROCYCLIC COMPOUNDS USEFUL AS BIFUNCTIONAL MODULATORS OF M3 RECEPTORS AND BETA- 2 RECEPTORS | ARGENTA DISCOVERY LTD (GB) | 2008-08-14 | — | — | WO | disclosed |
| CN-1082023-A | The medicine and the novel benzoic acid derivative that contain benzoic acid derivative | YAMANOUCHI PHARMA CO LTD (JP) | 1994-02-16 | — | — | CN | disclosed |
| EP-0332331-B1 | Thiazolidinedione hypoglycemic agents | PFIZER (US) | 1994-02-09 | — | — | EP | disclosed |
| US-5223522-A | Anticholesterol agents | PFIZER INC. (US) | 1993-06-29 | — | — | US | disclosed |
| US-5120754-A | Anticholesterol and antidiabetic agents | PFIZER INC. (US) | 1992-06-09 | — | — | US | disclosed |
| US-5061717-A | ANTICHOLESTEROL AGENTS | PFIZER INC. (US) | 1991-10-29 | — | — | US | disclosed |
| WO-1989008650-A1 | THIAZOLIDINEDIONE HYPOGLYCEMIC AGENTS | PFIZER INC. (US) | 1989-09-21 | — | — | WO | disclosed |
| EP-0332331-A2 | Thiazolidinedione hypoglycemic agents | PFIZER INC. (US) | 1989-09-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10927104-B2 | Ether compounds and uses thereof | EPCAM, ICAM1, SELE | ACHE 2846/4885PTGS2 1257/4885BCHE 2194/4885 |
| US-20220119350-A1 | COMPOUNDS FOR THE TREATMENT OF OCULAR DISEASE | ALDH1A2, SQOR, EYA3 | ACHE 373/4885PTGS2 30/4885BCHE 835/4885 |
| US-11092604-B2 | Glucose sensor molecule | GPR119, GCKR, IRS1 | ACHE 4755/4885PTGS2 4623/4885BCHE 4530/4885 |
| US-20200231582-A1 | ETHER COMPOUNDS AND USES THEREOF | EPCAM, ICAM1, SELE | ACHE 2846/4885PTGS2 1257/4885BCHE 2194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.